

1 **Psychiatric disorders and self-harm across 26 adult cancers: cumulative**  
2 **burden, temporal variation, excess years of life lost and unnatural**  
3 **causes of deaths**  
4  
5  
6  
7

8 Wai Hoong Chang<sup>1</sup>, Alvina G. Lai<sup>1</sup>  
9

10  
11  
12  
13  
14  
15 <sup>1</sup>Institute of Health Informatics, University College London, London, UK  
16  
17

18  
19 For correspondence: Alvina G. Lai ([Alvina.lai@ucl.ac.uk](mailto:Alvina.lai@ucl.ac.uk))  
20  
21

22 **Abstract**

23

24 ***Background***

25 Cancer is a life-altering event causing considerable psychological distress. However,  
26 population-representative variations in the total burden of psychiatric episodes across cancer  
27 types and treatment modalities have not been examined. We sought to estimate the risk of  
28 self-harm after incident psychiatric disorder diagnosis in patients with cancer, and the risk of  
29 unnatural deaths after self-harm.

30

31 ***Design, Setting, Participants***

32 Population-based cohort study with multiphase study designs. Population-based linked patient  
33 records in England (1998-2020) from primary care practices, hospitals, cancer registry and  
34 death registry were employed. We identified 459,542 individuals age  $\geq 18$  years with an  
35 incident diagnosis of a site-specific cancer of interest.

36

37 ***Main outcome measures***

38 Using outpatient and inpatient records, we identified patients with five psychiatric disorders of  
39 interest: depression, anxiety disorder, schizophrenia, bipolar disorder and personality  
40 disorder. Cumulative burden for all psychiatric events was estimated using the mean  
41 cumulative count method. We considered 10 cancer treatment regimens, 11 chemotherapy  
42 drug classes, deprivation status and 21 non-cancer comorbidities in stratified analyses.  
43 Propensity score matching was employed to identify controls who did not have any record of  
44 a psychiatric disorder of interest. For each psychiatric disorder category, we fitted a Cox  
45 regression model to estimate the risk of self-harm. We also estimated the risk of all-cause  
46 mortality and excess years of life lost comparing patients with and without psychiatric  
47 disorders. A separate matched cohort was generated to explore the risk of suicide and  
48 unnatural deaths following self-harm.

49

50 ***Results***

51 Depression was the most common psychiatric disorder in patients with cancer, where some  
52 of the highest cumulative burdens were observed in patients with testicular cancer (98.05 per  
53 100 individuals [CI: 83.08-127.25]), cervical cancer (78.74 [73.61-90.14]) and Hodgkin  
54 lymphoma (69.87 [61.05-69.48]) by age 60. Patients who received chemotherapy,  
55 radiotherapy and surgery had the highest cumulative burden of psychiatric disorders, while  
56 patients who received radiotherapy alone had the lowest burden. Patients treated with  
57 alkylating agent chemotherapeutics had the highest burden of psychiatric disorders while  
58 those treated with kinase inhibitors had the lowest burden. Among patients with cancer, 5,683  
59 individuals were identified as having an incident self-harm episode. A previous diagnosis of  
60 psychiatric disorder before self-harm was at least twice as prevalent than a subsequent  
61 diagnosis of psychiatric disorder where the prevalence ratio was the highest in patients with  
62 brain tumours (5.36, CI: 4.57-6.14). Younger individuals were more likely to be diagnosed with  
63 mental illness before the first self-harm episode. However, individuals from more deprived  
64 regions (2.46, CI: 2.32-2.60) and individuals with  $\geq 4$  pre-existing comorbidities (2.19, CI: 1.92-  
65 2.46) were less likely to be diagnosed with mental illness before self-harm. Patients with  
66 mental illness had a higher cumulative burden of self-harm events compared with matched  
67 controls. All mental illnesses were associated with an increased risk of subsequent self-harm,  
68 where the highest risk was observed within 12 months of the mental illness diagnosis. Risks  
69 of self-harm during the first year in matched cohorts were as follow: depression (adjusted HR  
70 44.1, CI: 34.0-57.1), anxiety disorder (HR 21.1, CI: 16.4-27.0) and schizophrenia (HR 7.5, CI:  
71 5.0-11.2). Patients with cancer and psychiatric disorder experienced excess years of life lost.  
72 Patients who harmed themselves were 6.8 times more likely to die of unnatural causes of  
73 death compared with controls within 12 months of self-harm (HR 6.8, CI: 4.3-10.7). The risk  
74 of unnatural death after 12 months was markedly lower (HR 2.0, CI: 1.5-2.7).

75

76 ***Conclusions***

77 This study quantifies the total burden of psychiatric events and self-harm in patients with  
78 cancer. The cumulative burden of psychiatric events varies across cancer type, treatment  
79 regimen and chemotherapy type. Incident psychiatric disorder diagnoses were significantly  
80 associated with increased risk of subsequent self-harm, where risks varied across psychiatric  
81 diagnostic categories and follow-up periods. Patients who harm themselves experienced the  
82 highest risk of dying from unnatural deaths within the first year of self-harm. We provide an  
83 extensive knowledge base to help inform collaborative cancer-psychiatric care initiatives by  
84 prioritising patients who are most at risk.

85

86

87 **Keywords:**

88 Cancer; psychiatric disorder; self-harm; suicide; cumulative burden; years of life lost

89

90

91 **Introduction**

92  
93 Mental illness is commonly found to be associated with an increased risk of mortality in  
94 patients with cancer<sup>1-3</sup>. Patients with cancer may experience significant psychological distress  
95 due to neuropsychiatric effects exerted by tumours, adverse reactions to physically  
96 demanding cancer treatment and substantial social and emotional impact (i.e., altered facial  
97 appearances) from cancer and its sequelae<sup>4</sup>. Cancer leaves permanent pathological  
98 alterations that imprint on people's lives even when signs of active disease are no longer  
99 present. These effects, compounded by residual disability and periods of inability to work,  
100 could lead to social issues that serve to magnify psychological distress. Yet, cancer  
101 management often overshadows the recognition and treatment of psychiatric disorders.  
102 Patients with pre-existing mental health conditions may be prone to relapse during their cancer  
103 journey, while individuals without a history of mental health may face competing demands  
104 from their cancer that could distract physicians from recognising and diagnosing psychiatric  
105 disorders. Studies have also shown that individuals are often reluctant to seek professional  
106 mental health care<sup>5</sup>; of 24% of patients diagnosed with moderate or severe psychiatric  
107 disorder, only 8% had ever sought professional help<sup>6</sup>. Notable barriers to mental health help-  
108 seeking include a preference for self-reliance, low perceived need and negative experience or  
109 dissatisfaction with previous healthcare encounters<sup>5</sup>. Individuals may also be worried about  
110 being labelled as mentally ill and may experience self-blame, which further prompts  
111 catastrophic emotional and behavioural reactions against themselves (self-harm or suicide)<sup>7,8</sup>.

112  
113 Systematic evidence of the total burden of psychiatric disorders, self-harm episodes and risk  
114 of suicide and unnatural deaths is essential to aid early identification and intervention of mental  
115 illness and suicidal thoughts. Detailed evidence is, however, lacking in this area. Real-world  
116 linked electronic health record data is uniquely well suited to address this question because:  
117 (1) it captures psychiatric and self-harm events in both community care and in-patient settings,  
118 (2) linkage to the cancer registry provide patient-level data on all cancer diagnoses and  
119 treatment regimens and (3) linkage to the death registry allows the complete ascertainment of  
120 cause of death. Our study seeks to: (1) estimate the variations in cumulative burden of five  
121 psychiatric disorders across 26 adult cancers stratified by treatment modalities and  
122 chemotherapy type, (2) estimate temporal variations in the first diagnosis of psychiatric  
123 disorder in relation to the time of the first self-harm event (prevalence ratios are calculated),  
124 (3) estimate the total burden of incident self-harm events (including recurrent events) after  
125 diagnosis of psychiatric disorder, (4) examine the subsequent risk of self-harm associated  
126 each psychiatric disorder at different timeframes, (5) examine mortality risk and excess years  
127 of life lost comparing patients with and without incident psychiatric disorder diagnosis and (6)  
128 investigate the risk of natural and unnatural deaths following self-harm. Our study identifies  
129 the timeframe and risk factors that can be used by physicians and family members to better  
130 monitor the mental health of patients with cancer. Psychiatric disorders are treatable  
131 modifiable risk factors, and efforts to recognise, diagnose and treat these conditions could  
132 positively affect the quality of life after cancer.

133  
134

135 **Methods**

136

137 ***Linked electronic health record data sources***

138

139 Two primary care linked electronic health record (EHR) databases, GOLD and Aurum, from  
140 the Clinical Practice Research Datalink (CPRD) were used. Information governance approval  
141 was obtained from the Medicines Healthcare Regulatory Authority Independent Scientific  
142 Advisory Committee (19\_222 21\_000593). The original dataset contains 5,343,578 individuals  
143 during the study period of 01-01-1998 to 31-10-2020. Primary care EHRs were linked to the  
144 secondary care Hospital Episode Statistics (HES), Office for National Statistics (ONS) death  
145 registry, patient-level Index of Multiple Deprivation (IMD; an area-based proxy for  
146 socioeconomic deprivation) and the National Cancer Registration and Analysis Service  
147 (NCRAS). Detailed cancer registration data (cancer site, behaviour, morphology and  
148 treatment information) were available in NCRAS. Chemotherapy drug details were obtained  
149 from the Systemic Anti-Cancer Treatment (SACT) dataset within NCRAS while radiotherapy  
150 details were obtained from the Radiotherapy (RTDS) dataset.

151

152

153 ***Multiphase study designs***

154

155 We identified incident primary site-specific cancer cases in individuals aged 18 years or older.  
156 Incident cancers were defined as the first diagnosis of cancer occurring at least 1 year after  
157 the start of the up to standard (UTS) date. The UTS date is a practice-based quality metric  
158 and an indication of research-quality patients and periods of quality data recording<sup>9</sup>. Patients  
159 had at least one year of UTS follow-up prior to the start of the study period (01-01-1998).

160

161 First, we analysed the cumulative burden of psychiatric disorders after cancer diagnosis. Since  
162 patients may experience recurrent psychiatric events, we employed the mean cumulative  
163 count method to not only capture the first occurrence of the event, but also subsequent  
164 occurrences. The cumulative burden method reflects a summarisation of all events that occur  
165 in a population by a given time<sup>10</sup> (see cumulative burden section for details).

166

167 Second, we analysed temporal variations in the first psychiatric disorder diagnosis in relation  
168 to the first event of self-harm. The proportion of patients being diagnosed with a psychiatric  
169 disorder (for the first time) before and after the first self-harm event was calculated and plotted.

170

171 Third, we analysed the cumulative burden of recurrent self-harm events after the diagnosis of  
172 psychiatric disorders in patients with cancer.

173

174 Fourth, we estimated the risk of self-harm after diagnosis of psychiatric disorder in patients  
175 with cancer. We identified incident cases of psychiatric disorder (patients who had a history of  
176 psychiatric disorder before cancer diagnosis were excluded) (Figure S1). Patients with a  
177 history of self-harm before or at the time of the first diagnosis of psychiatric disorder were also  
178 excluded. For each psychiatric disorder, the first date of diagnosis (index date) was used as  
179 the date that follow-up started. Controls were identified by propensity score matching by age  
180 at cancer diagnosis, cancer type, sex, Index of Multiple Deprivation and primary care practice  
181 ID. Matching was performed using the optimal pair matching algorithm in the R matchit  
182 package based on the premise that the sum of the absolute pairwise distances in the matched  
183 sample was as small as possible. Unlike the nearest-neighbour matching, optimal matching  
184 ensures that within-pair distances remain small. For controls, the index date of its  
185 corresponding matched case was the date that follow-up started. Patients were followed up  
186 until self-harm, date of deregistration from the practice, death, or date of administrative  
187 censoring (31-10-2020), whichever occurred first (Figure S1).

188

189 Fifth, we estimated the risk of suicide and other causes of death following self-harm in patients  
190 with cancer. We identified incident self-harm episodes (patients who had a history of self-harm  
191 before cancer diagnosis were excluded). The first date of self-harm (index date) was used as  
192 the date that follow-up started. Controls were identified by propensity score matching by age  
193 at cancer diagnosis, cancer type, sex, Index of Multiple Deprivation and primary care practice  
194 ID. For controls, the index date of its corresponding matched case was the date that follow-up  
195 started. Patients were followed up until death, date of deregistration from the practice or date  
196 of administrative censoring (31-10-2020), whichever occurred first (Figure S2).

197  
198

### 199 **Electronic health record phenotypes**

200

201 All electronic health record (EHR) phenotypes were obtained from the open-access CALIBER  
202 phenotype library (<https://portal.caliberresearch.org/>) and have been previously validated<sup>11-13</sup>.  
203 Phenotypes for CPRD GOLD were generated using version 2 Read codes. Phenotypes for  
204 CPRD Aurum data were generated using a combination of SNOMED CT, Read version 2 and  
205 EMIS Web codes. Phenotypes for HES were generated in ICD-10. EHR phenotypes for self-  
206 harm were obtained from a previous study<sup>14</sup>. We employed primary care, secondary care and  
207 NCRAS records to identify patients aged  $\geq 18$  years with an incident primary site-specific  
208 cancer. We considered 26 cancer types: bladder, bone, brain, breast, cervix, colon and  
209 rectum, gallbladder and biliary tract, Hodgkin lymphoma, kidney and renal pelvis, leukaemia,  
210 liver and intrahepatic bile duct, lung and bronchus, melanoma, multiple myeloma, non-  
211 Hodgkin lymphoma, oesophagus, oropharynx, ovary, pancreas, prostate, small intestine,  
212 spinal cord and nervous system, stomach, testis, thyroid and uterus. We considered five  
213 psychiatric diagnostic categories: depression, anxiety disorders, schizophrenia, schizotypal  
214 and delusional disorders, bipolar affective disorder and mania and personality disorders.

215

216 Prevalent non-cancer physical comorbidities recorded before index date entry were identified  
217 from primary and secondary care records. We considered the following 21 comorbidities: heart  
218 failure, chronic obstructive pulmonary disease, HIV, hepatic disorders (i.e., alcoholic liver  
219 disease, non-alcoholic fatty liver disease, hepatic failure, liver fibrosis and cirrhosis and portal  
220 hypertension), stroke (i.e., ischaemic stroke, stroke not otherwise specified, transient  
221 ischaemic attack, intracerebral haemorrhage and subarachnoid haemorrhage), myocardial  
222 infarction, vascular disease (i.e., peripheral arterial disease, Raynaud's syndrome, and venous  
223 thromboembolic disease) and abnormal glucose metabolism (i.e., type 1 and type 2 diabetes,  
224 diabetic neurological complications and diabetic ophthalmic complications). For stratified  
225 analyses, patients were divided into the following categories: 0 additional comorbidity (i.e.,  
226 patients without diagnosis of any of the above non-cancer comorbidities), 1 additional  
227 comorbidity, 2 comorbidities, 3 comorbidities and 4+ comorbidities.

228

229 We analysed ten cancer treatment variables: (i) all chemotherapy (i.e., everyone who received  
230 chemotherapy), (ii) all radiotherapy, (iii) all surgery, (iv) chemotherapy only (i.e., individuals  
231 who received chemotherapy only and nothing else), (v) radiotherapy only, (vi) surgery only,  
232 (vii) chemotherapy and radiotherapy, (viii) chemotherapy and surgery, (ix) radiotherapy and  
233 surgery, (x) chemotherapy, radiotherapy and surgery. We considered 11 types of  
234 chemotherapy drug variables: (i) alkylating agents, (ii) anthracyclines, (iii) antimetabolites, (iv)  
235 biological response modifiers including monoclonal antibodies, (v) chemotherapy not  
236 otherwise specified, (vi) hormonal agents including corticosteroid hormones and sex  
237 hormones, (vii) kinase inhibitors, (viii) non-anthracycline antitumour antibiotics, (ix) plant  
238 alkaloids and natural products excluding vinca alkaloids, (x) platinum agents and (xi) vinca  
239 alkaloids. Cause-specific mortality was defined using the underlying cause of death code as  
240 recorded in the ONS death registry. Natural deaths consist of all ICD-10 codes, excluding V01-  
241 Y98. Unnatural deaths include V01-Y98 and suicides (including open verdicts X60-X84 and  
242 Y10-Y34)<sup>14</sup>.

243

244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287

### **Statistical analyses**

We estimated the cumulative burden of five psychiatric disorders and self-harm episodes using the previously described and validated mean cumulative count (MCC) method<sup>10,15</sup>. Given that psychiatric and self-harm episodes can recur, we employed the MCC method which considers recurrent events – cumulative incidence only considers the first occurrence of the event in each individual. We analysed the burden of recurrent events in the presence of competing risks. We considered death as a competing risk event as it precludes the occurrence of other events of interest. MCC can adopt any positive number, as it is an estimation of the mean count of events per individual within a given population (not the probability of developing the event). Cumulative burden of psychiatric disorders following cancer diagnosis was estimated as the average number of psychiatric events occurring at a given age. MCC of 0.5 at age 40 means that there is an average of 0.5 events occurring per individual at age 40 (i.e., 50 events per 100 individuals). Cumulative burden of self-harm following psychiatric disorder diagnosis was estimated as the average number of self-harm events occurring at a given time of follow-up (i.e., time from psychiatric disorder diagnosis to self-harm). MCC of 0.16 by 5 years of follow-up means that there is an average of 16 events per 100 individuals at 5 years. 95% confidence intervals (CIs) were generated using the bootstrap percentile method<sup>10</sup>.

We performed Cox proportional hazards regression to determine: 1) the risk of self-harm after psychiatric disorder diagnosis and 2) the risk of suicide and other causes of death following self-harm. Cox regression was performed on matched cohorts and further adjusted for non-cancer comorbidities, cancer treatment and the presence of additional psychiatric disorders. Proportional hazards assumption was evaluated using the Schoenfeld residuals. We also estimated the cumulative incidence for: 1) all-cause mortality after psychiatric disorder diagnosis and 2) all-cause and cause-specific mortality after self-harm. Analyses on specific causes of death were adjusted for the competing risk of dying from other causes. Years of life lost (YLL) refers to the number of years lost in patients with a given disease and was estimated using the R package lillies<sup>16</sup>, which was validated by other studies<sup>17–19</sup>. We calculated excess YLL as the average YLL (in years) that patients with psychiatric disorders experience from the time of diagnosis in excess to those experienced by the control population (i.e., individuals without psychiatric disorders) of the same age. Excess YLL was estimated based on the age of psychiatric disorder onset at ages 30, 40, 50, 60 and 70. Analyses were performed using R (3.6.3) with the following packages: tidyverse, tableone, lillies, reshape, splines, survival, survminer, etm, mstate, cmprsk, DataCombine, data.table, ggsci and pals.

### **Patient and public involvement**

No patients were involved in the implementation of the study as anonymised data was obtained from the Clinical Practice Research Datalink without direct contact with patients.

## 288 **Results**

289

290

### 291 ***Patients with testicular cancer had the highest burden of psychiatric disorders*** 292 ***compared with other cancer types***

293

294 Between 1998 and 2020, we identified 459,542 individuals age  $\geq 18$  years with an incident  
295 diagnosis of a site-specific cancer of interest. Patient characteristics were presented in Table  
296 S1. We analysed cumulative burden of five psychiatric disorders (depression, anxiety  
297 disorders, schizophrenia, schizotypal and delusional disorders, bipolar affective disorder and  
298 mania and personality disorders) following cancer diagnosis and compared results across 26  
299 cancer diagnostic groups. Cumulative burden was the highest for depression, followed by  
300 anxiety disorders (Figure 1A, Table S2). At age 60, for example, cumulative burdens per 100  
301 individuals for depression ranked from highest to lowest by cancer type were as follow: testis  
302 (98.05 [CI: 83.08-127.25]), cervix (78.74 [73.61-90.14]), Hodgkin lymphoma (69.87 [61.05-  
303 69.48]), spinal cord and nervous system (60.37 [33.8-63.46]), thyroid (52.69 [40.74-60.98]),  
304 bone (39.17 [38.06-51.09]), breast (34.35 [33.77-35.33]), melanoma (25.98 [25.02-27.23]),  
305 oropharynx (24 [21.4-27.61]), ovary (21.92 [19.96-23.22]), small intestine (18.08 [17.47-  
306 27.52]), kidney and renal pelvis (16.24 [13.51-18.27]), uterus (14.44 [13.36-16.66]), non-  
307 Hodgkin lymphoma (13.93 [12.64-14.28]), leukaemia (13.84 [12.03-14.74]), brain (11.93 [10.8-  
308 13.33]), multiple myeloma (8.5 [6.4-9.84]), colon and rectum (5.7 [5.35-6.09]), bladder (4.28  
309 [4.19-5.32]), oesophagus (3.98 [3.66-3.98]), stomach (3.2 [2.69-3.38]), lung and bronchus  
310 (3.11 [2.58-3.42]), gallbladder and biliary tract (3.04 [2.47-3.68]), liver and intrahepatic bile  
311 duct (2.75 [2.47-3.65]) and pancreas (2.42 [1.94-3.42]), prostate (2.4 [2.15-2.67]) (Figure 1A,  
312 Table S2). Patients with testicular cancer had the highest burden across all psychiatric  
313 disorders - cumulative burdens at age 60 were as follow: depression (98.05 per 100 individuals  
314 [83.08-127.25]), anxiety (83.54 [78.03-90.59]), schizophrenia (8.24 [4.72-11.76]), personality  
315 disorders (5.42 [0.20-15.75]) and bipolar disorders (2.50 [1.59-3.13]).

316

317

### 318 ***Impact of cancer treatment on the burden of psychiatric disorders***

319

320 When comparing across treatment modalities, patients who received all three chemotherapy,  
321 radiotherapy and surgery had the highest cumulative burden of psychiatric disorders (Figure  
322 1B, Table S3). At age 60, cumulative burdens were: depression (28.23 per 100 individuals  
323 [27.07-29.94]), anxiety (19.66 [19.00-20.76]), schizophrenia (2.53 [2.10-2.96]), personality  
324 disorders (0.05 [0.02-0.07]) and bipolar disorders (1.94 [1.50-2.03]). At age 80, cumulative  
325 burdens were: depression (68.77 [67.17-71.07]), anxiety (52.70 [50.89-54.25]), schizophrenia  
326 (12.50 [11.83-13.75]), personality disorders (0.16 [0.13-0.20]) and bipolar disorders (5.18  
327 [4.05-5.64]). By contrast, the lowest burden of psychiatric disorders was observed in patients  
328 who received radiotherapy alone. At age 60, cumulative burdens were: depression (8.09 [7.81-  
329 8.86]), anxiety (5.82 [5.55-6.60]), schizophrenia (0.80 [0.75-0.97]), personality disorders (0.09  
330 [0.02-0.15]) and bipolar disorders (0.29 [0.20-0.46]).

331

332

### 333 ***Patients who received alkylating agents for chemotherapy had the highest burden of*** 334 ***psychiatric disorders***

335

336 At age 60, cumulative burdens in patients who were treated with alkylating agents were:  
337 depression (47.55 per 100 individuals [45.31-51.21]), anxiety (37.47 [35.47-42.24]),  
338 schizophrenia (5.76 [4.84-6.18]), personality disorders (0.73 [0.60-0.97]) and bipolar disorders  
339 (3.14 [2.41-4.12]) (Figure 1C, Table S4). Patients who received kinase inhibitor treatment, by  
340 contrast, had the lowest burden of psychiatric disorders – cumulative burden at age 60 were:  
341 depression (24.46 [16.95-30.94]), anxiety (10.20 [6.85-11.93]), schizophrenia (1.14 [0.62-  
342 2.05]), personality disorders (0.14 [0.00-0.14]) and bipolar disorders (3.99 [0.05-4.03]).

343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397

### ***A diagnosis of previous psychiatric disorder was common in patients who self-harm***

Among patients with cancer, 5,683 individuals were identified as having an incident self-harm episode (self-harm event after cancer diagnosis) (Figure S2). We estimated temporal variation in the first diagnosis of a psychiatric disorder in relation to the time of the first episode of self-harm. We observed that across cancer types, a previous diagnosis of psychiatric disorder prior to self-harm was at least twice as prevalent than a subsequent diagnosis of psychiatric disorder (Figure 2). Prevalence ratio was the highest in patients with brain tumours (5.36, CI: 4.57-6.14), followed by prostate cancer (4.30, CI: 4.08-4.52), Hodgkin lymphoma (4.17, CI: 2.98 -5.37), testicular cancer (3.96, CI: 2.87-5.04) and melanoma (3.84, CI: 3.44-4.24). By contrast, patients with lung cancer had the lowest prevalence ratio (2.05, CI: 1.90-2.20) (Figure 2A). Younger individuals were more likely to be diagnosed with mental illness before the first self-harm episode compared with older individuals. For example, individuals aged 18-34 were 4.3 times (CI: 3.69-5.06) more likely to be diagnosed with a psychiatric disorder prior to self-harm, compared with individuals aged 51-65 (2.66, CI: 2.54-2.77) (Figure 2B). Patients from the most deprived regions had a lower prevalence ratio (2.46, CI: 2.32-2.60) than those from least deprived regions (3.68, CI: 3.52-3.84), suggesting that socioeconomic deprivation had an impact on previous help-seeking behaviour before self-harm (Figure 2C). Similarly, patients with a high number of pre-existing conditions were less likely to be diagnosed with a psychiatric disorder before self-harm. Prevalence ratio for individuals with 0 non-cancer comorbidities was 3.24 (CI: 3.17-3.31) versus 2.19 (CI: 1.92-2.46) in individuals with 4+ comorbidities (Figure 2D).

### ***Total burden of non-fatal self-harm events and risk of self-harm following psychiatric disorder diagnosis***

Propensity score matching was used to identify patients with and without a specific psychiatric disorder (Figure S1). The number of patients with incident psychiatric disorder were as follow: depression (21,609), anxiety disorder (20,070), schizophrenia (7,679), bipolar disorder (557) and personality disorder (194). The number of matched controls for each psychiatric disorder were as follow: depression (75,087), anxiety disorder (67,887), schizophrenia (23,130), bipolar disorder (1,636) and personality disorder (628) (Figure S1). Patient characteristics of the five diagnostic groups for cases and controls were summarised in Table S1. The cumulative burden of self-harm episodes was substantially higher in individuals with a prior diagnosis of psychiatric disorder compared. Across all control cohorts, the cumulative burdens of self-harm were less than 1 event per 100 controls at 10 years of follow-up, except for matched schizophrenia controls where the burden of self-harm was 1.36 events (CI: 1.16-1.52) (Figure 3A, Table S5). By contrast, cumulative burden of self-harm events per 100 individuals with mental illness at 1 year of follow-up were: depression (4.65, CI: 4.41-4.95), anxiety disorder (2.81, CI: 2.64-2.95), schizophrenia (1.16, CI: 0.95-1.44), personality disorder (7.75, CI: 4.65-9.29) and bipolar disorder (7.20, CI: 5.22-8.49). At 10-years of follow-up, the burden of self-harm were: depression (9.83 events per 100 individuals, CI: 9.73-10.45), anxiety disorder (7.93, CI: 7.81-8.35), schizophrenia (6.63, CI: 5.92-6.94), personality disorder (11.44, CI: 6.91-11.37) and bipolar disorder (43.88, CI: 40.72-49.56) (Figure 3A, Table S5).

All psychiatric disorders were significantly associated with an increased risk of subsequent self-harm (Figure 3B, Table S6). Self-harm risk was observed to change according to the length of follow up, with significantly higher hazard ratios (HRs) observed within 12 months of psychiatric disorder diagnosis. Individuals with depression were estimated to be 44 times more likely to self-harm during the first year (adjusted HR 44.1, CI: 34.0-57.1). Patients with anxiety disorder or schizophrenia were 21 times (HR 21.1, CI: 16.4-27.0) and 7 times (HR 7.5, CI: 5.0-11.2) more likely to self-harm, respectively, during the first year (Figure 3B, Table S6). The risk of self-harm markedly decreased over subsequent years of follow-up: depression (HR 5.2,

398 CI: 4.6-5.8), anxiety disorder (HR 4.0, CI: 3.5-4.5), schizophrenia (HR 2.9, CI: 2.4-3.5), bipolar  
399 disorder (HR 12.1, CI: 7.5-19.5) and personality disorder (HR 9.0, CI: 2.9-28.5) (Figure 3B,  
400 Table S6).

401  
402

403 ***Patients with cancer and mental illness experienced excess years of life lost***

404

405 Across all psychiatric disorders, the cumulative incidences for all-cause mortality were  
406 consistently higher in cases than controls (Figure 4A). We estimated excess years of life lost  
407 (YLL) which is the average number of years that patients with psychiatric disorder lose in  
408 excess of that found in patients without psychiatric disorder of the same age. Excess YLLs for  
409 each psychiatric disorder across different age of onset were displayed as radar plots (Figure  
410 4B, Table S7). Younger age of psychiatric disorder onset was consistently associated with  
411 higher excess YLL. At age 30, patients with anxiety disorder lose 28.3 years in excess of their  
412 matched controls. By comparison, excess YLL in patients diagnosed with schizophrenia at  
413 age 30 was 32.2 years. At age 60, excess YLLs ranked from highest to lowest were as follow:  
414 personality disorder (16.0, CI: 13.8-18.9), schizophrenia (14.1, CI: 13.7-14.5), bipolar disorder  
415 (13.3, CI: 11.7-14.9), depression (12.9, CI: 12.6-13.1) and anxiety disorder (12.1, CI: 11.8-  
416 12.3) (Figure 4B, Table S7).

417

418

419 ***Patients who self-harm had the highest risk of unnatural deaths within 12 months of***  
420 ***self-harm***

421

422 Propensity score matching was used to identify cases (with self-harm) and controls (without  
423 self-harm) for analyses on cause-specific mortality risk following self-harm. We identified  
424 5,683 individuals with incident self-harm episodes and 18,407 matched controls (Figure S2).  
425 Adults who harmed themselves were 6.8 times more likely to die of unnatural causes of death  
426 compared with controls within 12 months of self-harm (HR 6.8, CI: 4.3-10.7). The risk of  
427 unnatural death after 12 months was markedly lower (HR 2.0, CI: 1.5-2.7) (Figure 5A, Table  
428 S8). Cumulative incidence curves also demonstrated that the self-harm group had an  
429 increased risk of dying from unnatural deaths, after adjusting for competing risk of natural  
430 deaths (Figure 5B).

431

## 432 **Discussion**

433

### 434 ***Principal findings***

435

436 We present the first study examining mental illness and self-harm events across 26 cancer  
437 types. Utilising data from primary care practices and hospitals, we quantified the total burden  
438 (not just the first event) of psychiatric disorder and self-harm. We also examined the  
439 prevalence of mental health diagnoses before and after self-harm and demonstrate that  
440 previous diagnoses of psychiatric disorders are important predictors of self-harm. We  
441 observed considerable differences in the risk of self-harm across psychiatric disorders.  
442 Patients with depression had the highest risk of self-harm, especially within 12 months of  
443 diagnosis, suggesting that patients require higher vigilance during this initial critical period.  
444 Interestingly, we found that schizophrenia was associated with a lower risk of self-harm – a  
445 finding that is corroborated by another study conducted in Hong Kong<sup>20</sup>. Patients with mental  
446 illness were significantly more likely to experience premature mortality. Furthermore, the risk  
447 of suicide and other causes of death were significantly higher in patients who harm  
448 themselves, particularly within 12 months of the first self-harm episode.

449

450 Two models have been proposed as contributing to the underlying cause of psychiatric  
451 disorders in patients with cancer: the biopsychosocial model and the neuropsychiatric effects  
452 of cancer and cancer treatment model<sup>4</sup>. The biopsychosocial model posits that biological,  
453 psychological and social factors contribute to chronic periods of psychological stress. Patients  
454 experiencing chemotherapy-induced alopecia are more likely to experience depression due to  
455 poorer body image and psychosocial well-being<sup>21</sup>. Patients may also experience health  
456 anxiety and fear of cancer recurrence, which can be triggered by internal (e.g., physical  
457 symptoms) and external cues (e.g., medical consultations, regrets about treatment decisions  
458 and media exposure)<sup>22</sup>. Coping with a life-threatening diagnosis of cancer may reinforce  
459 abnormal behaviours such as antisocial, narcissistic and obsessive-compulsive tendencies  
460 that define personality disorders<sup>23</sup>.

461

462

### 463 ***Comparison with other studies***

464

#### 465 ***Neuropsychiatric effects of cancer***

466 A meta-analysis found that the pooled mean prevalence of depression in patients with cancer  
467 ranged from 8% to 24%, which varies across cancer types and cancer treatments<sup>24</sup>. Similarly,  
468 another study demonstrated that 23% and 19% of patients with cancer experienced  
469 depression and anxiety, respectively where depression was more prevalent in patients in-  
470 patient settings<sup>25</sup>. Patients with pancreatic cancer had higher levels of interleukin-6 cytokines,  
471 which is correlated with the severity of depressive symptoms<sup>26</sup>, but interestingly not with other  
472 measures of psychological distress. Patients with cancer may experience paraneoplastic  
473 neurologic syndromes, which are caused by immunological reactions to tumours.  
474 Paraneoplastic syndrome may induce psychiatric changes such as depression, personality  
475 disturbances, hallucinations and psychosis<sup>27</sup>. Patients experiencing paraneoplastic cerebellar  
476 degeneration exhibit psychiatric symptoms, for example, limbic encephalitis seen in patients  
477 with lung cancer presents with anxiety and depression<sup>28</sup>.

478

#### 479 ***Neuropsychiatric effects of cancer treatment***

480 The first presentation of bipolar disorder typically occurs at younger ages, however, recent  
481 studies found that 10% of elderly individuals develop the first onset of manic episodes later in  
482 life<sup>29</sup>. Patients with bipolar disorder experience recurring manic and depressive episodes,  
483 which can be exacerbated by cancer or its treatment. Although mania is less commonly seen  
484 in patients with cancer, it may be precipitated by steroids used as part of cancer treatment<sup>30</sup>  
485 or mania secondary to brain cancer. Glucocorticoid steroid-induced manic and hypomanic  
486 symptoms are common, and symptoms are thought to be dose-dependent<sup>31</sup>. Another case

487 report found that the chemotherapy 5-Fluorouracil induced manic episodes in a patient without  
488 a history of psychiatric illness<sup>32</sup>. Since 5-Fluorouracil could penetrate the blood-brain barrier,  
489 it is linked to neurotoxicity<sup>33</sup> and mania may be caused by injury to neurotransmitter pathways.  
490 There have been limited studies on mania caused by extracerebral cancer and  
491 neuropsychiatric symptoms reported in these situations are either triggered by steroids or  
492 paraneoplastic syndromes due to antineuronal antibodies<sup>34</sup>. Two reports described first-onset  
493 mania in lung cancer and another demonstrates recurring mania in a patient with lung  
494 adenocarcinoma and a previous diagnosis of bipolar disorder<sup>35,36</sup>.

495  
496

#### 497 *Impact of psychiatric disorders on cancer prognosis and subsequent self-harm behaviour*

498 We have shown that psychiatric disorders have a major impact on life after cancer diagnosis  
499 where patients with psychiatric illnesses had a higher incidence of mortality and experienced  
500 excess years of life lost. Patients with schizophrenia are more likely to receive palliative care  
501 and experience premature mortality<sup>37</sup>, suggesting that disparities in health and cancer care  
502 exist and are influenced by the pervasive stigma of mental illness. High-intensity cancer care  
503 is associated with an increased risk of psychomotor agitation, paranoid delusions and  
504 recurrence of psychotic symptoms<sup>38</sup>. There has been very limited research exploring the risk  
505 of suicide and self-harm in patients with both cancer and schizophrenia. In general, patients  
506 with schizophrenia are 5 times more likely to commit suicide<sup>39</sup>. We also found that the risk of  
507 self-harm was the highest within 12 months of mental health diagnosis, suggesting that  
508 patients who are experiencing active psychological symptoms in earlier stages of the disease  
509 are more likely to harm themselves. In these high-risk patients, a lower threshold for  
510 psychiatric consultation and intervention may be beneficial to reduce self-harm risk. Patients  
511 with personality disorders are often rigid and inflexible and such behaviours may affect cancer  
512 progression either through the maintenance of an unhealthy lifestyle or the inability to cope  
513 with cancer, treatments and changes in life<sup>23</sup>. Patients with certain personality traits can feel  
514 alienated. Neuroticism is linked to poorer quality of life after cancer treatment in patients with  
515 breast cancer<sup>40</sup>. Neuroticism is also associated with long-term physical (e.g., peripheral  
516 neuropathy and tinnitus) and mental (poor self-esteem and unhealthy lifestyle) morbidities in  
517 patients with testicular cancer<sup>41</sup>. These patients may require additional support to help them  
518 better adapt to life with cancer.

519  
520

#### 521 ***Strengths and limitations***

522

523 First, this is the most comprehensive study examining psychiatric disorders across 26 adult  
524 cancers, excess mortality due to mental illness, risk of self-harm and risk of suicide and other  
525 causes of deaths using a single population-based cohort. The use of population-based data  
526 means that our findings are generalisable. Second, given that we have employed linked health  
527 records from primary care practices and hospitals, a particular strength is the ascertainment  
528 of all psychiatric and self-harm events in ambulatory and in-patient settings. Unlike in studies  
529 based on in-patient hospital records<sup>20</sup>, our results are less likely to be affected by biases due  
530 to under-hospitalisation or underdiagnosis of psychiatric disorders. We were able to capture  
531 mild cases managed in community primary care. Third, we relied on clinically recorded  
532 diagnoses of psychiatric disorders and self-harm episodes, which means that as opposed to  
533 self-reported events, our study is free of reporting biases. Fourth, we were able to examine  
534 the effects of cancer treatment type and chemotherapy type on subsequent psychiatric events  
535 as detailed information on cancer treatment is available from the cancer registry. Fifth, linkage  
536 to the national death registry enabled the analyses on cause-specific mortality with complete  
537 case ascertainment. Sixth, our study employs the mean cumulative count method to estimate  
538 the total burden of psychiatric and self-harm episodes over time. All other studies used the  
539 cumulative incidence method, which only considers the first event, thereby underestimating  
540 the total burden of recurring mental illness and self-harm.

541

542 We outline several limitations. While our use of population-based records provides robust and  
543 representative data, there remains a risk of underreporting of self-injurious behaviour due to  
544 stigma, particularly among more affluent communities. Our analyses were adjusted for  
545 socioeconomic deprivation to reduce the impact of these biases. Suicides may be  
546 underestimated as we have used ICD codes on death certificates as we do not have access  
547 to coroners' reports. Coroners recording a suicide verdict must indicate suicidal intent beyond  
548 a reasonable doubt or else an open or accidental verdict is returned<sup>42</sup>. To address this  
549 problem, we have included open verdicts in our analyses as recommended by others<sup>14,42</sup>. We  
550 have not considered treatments for psychiatric disorders. The effects of psychiatric  
551 interventions on cancer survivorship can be explored in the future.

552  
553

### 554 ***Implications for policymakers, healthcare professionals, carers and patients***

555

556 The variations in the burden of psychiatric disorders according to cancer diagnostic category,  
557 treatment type and chemotherapy type can help inform targeted prevention strategies aimed  
558 at high-risk groups. We outline three areas for consideration: 1) early recognition and  
559 treatment of psychiatric conditions and effective monitoring after self-harm episode, 2)  
560 collaborative psychiatric and cancer care and 3) managing cancer treatment-disruptive  
561 behaviours.

562

563 Psychiatric illness may present at any point in the cancer journey. A Danish study observed  
564 an increase in incidence rates of brain and lung cancers upon the first-time psychiatric in-  
565 patient or outpatient contact. As it is not likely that the psychiatric condition itself would cause  
566 an immediate and sudden increase in cancer risk, the authors concluded that psychiatric  
567 disorders may represent one of the earliest manifestations of cancer<sup>43</sup>. This suggests that  
568 screening for psychiatric symptoms in cancers with paraneoplastic potential may aid in early  
569 diagnosis and treatment of both cancer and psychiatric disorder. Slow-growing cancers such  
570 as meningiomas produce psychiatric symptoms before neurological symptoms become  
571 apparent<sup>44</sup>. An Evidence-Based Care guideline for managing depression in patients with  
572 cancer proposed eight specific recommendations<sup>45</sup>: (i) screening patients with cancer for  
573 depression, (ii) provide psychoeducation, destigmatise depression and investigate medical  
574 contributors to depression (i.e., vitamin B12, iron and folate levels and hypothyroidism), (iii)  
575 provide pharmacologic and psychological interventions, (iv) assess depression severity and  
576 follow stepped care approach, (v) consider collaborative care interventions involving  
577 oncologists, primary care practitioners and psychiatrists, (vi) referral to mental health  
578 specialists where there is a risk of self-harm, (vii) consider psychological therapies such as  
579 cognitive behavioural therapy and (viii) consider the use of antidepressant medication for  
580 severe depression.

581

582 Prescribing of antidepressants will need to take into account potential contraindications or  
583 drug interactions with cancer therapy. For example, the SSRI antidepressant Fluoxetine  
584 should be avoided in patients receiving tamoxifen treatment for breast cancer due to adverse  
585 drug interactions and increased risk of death<sup>46</sup>. A randomised trial (SMaRT Oncology-2) found  
586 that an integrated collaborative care model for depression in patients with cancer resulted in  
587 a better quality of life, health, reduced anxiety, pain and fatigue<sup>47</sup>. Patients subjected to the  
588 integrated cancer-depression care model received intensive therapy (antidepressant drugs  
589 and face-to-face psychological therapy), which highlights the importance of collaborative care  
590 approaches in achieving sustained treatment effects with a marginal increase in cost.

591

592 Disruptive behaviour in patients with psychiatric illness may interfere with cancer treatment  
593 and continuing care. Unlike mental health physicians, oncologists may not receive adequate  
594 training in dealing with behavioural problems and there has been limited guidance on  
595 managing clinical and legal risks associated with these clinically complex scenarios. Some  
596 institutes have developed policies to help physicians respond effectively to uncooperative and

597 disruptive behaviour. For example, the main principles are to focus on problem behaviours in  
598 a non-punitive manner, introduce mental health consultation early in the cancer treatment  
599 pathway, design individualised responses to patient's behaviour and set realistic expectations  
600 of behaviour<sup>48</sup>. Dealing with treatment-disruptive behaviour can be exhausting, hence,  
601 multidisciplinary support for the primary physician is crucial especially in the ambulatory  
602 oncology setting.

603

604

### 605 **Conclusions**

606

607 Patients with both cancer and mental illness experience premature mortality and are at greater  
608 risk of self-harm. Gaining awareness of health disparities represents a significant step towards  
609 improving survival and well-being in the long term. Our work may inform new initiatives of  
610 integrated collaborative care to identify patients who are most at risk, to inform resource  
611 allocation, to identify patient and institutional barriers to implementation and to justify the  
612 delivery of a patient-centric model of care.

613

614 **Data sharing**

615 The data used in this study are available on successful ethics application to the Clinical  
616 Practice Research Datalink (CPRD). All summarised data and results are made available as  
617 supplementary materials.

618

619

620 **Declaration of interests**

621 None declared.

622

623

624 **Acknowledgements**

625 This research uses data provided by patients and collected by the NHS as part of their routine  
626 care.

627

628

629 **Authors contribution**

630 WHC and AGL conceived and designed the study. WHC undertook literature search. WHC  
631 and AGL analysed the data and interpreted the results. AGL supervised the research. WHC  
632 wrote the initial manuscript draft. AGL revised the manuscript draft. All authors read and  
633 approved the final manuscript.

634

635

636 **Funding**

637 AGL is supported by funding from the Wellcome Trust (204841/Z/16/Z), National Institute for  
638 Health Research (NIHR) University College London Hospitals Biomedical Research Centre  
639 (BRC714/HI/RW/101440), the Academy of Medical Sciences (SBF006\1084), NIHR Great  
640 Ormond Street Hospital Biomedical Research Centre (19RX02) and the Health Data Research  
641 UK Better Care Catalyst Award (CFC0125). The funders had no role in study design, data  
642 collection and analysis, decision to publish, or preparation of the manuscript.

643

644 **References**

- 645
- 646 1 Kisely S, Crowe E, Lawrence D. Cancer-related mortality in people with mental  
647 illness. *JAMA psychiatry* 2013; **70**: 209–17.
- 648 2 Musuuza JS, Sherman ME, Knudsen KJ, Sweeney HA, Tyler C V, Koroukian SM.  
649 Analyzing excess mortality from cancer among individuals with mental illness. *Cancer*  
650 2013; **119**: 2469–76.
- 651 3 Lin J, McGlynn KA, Carter CA, *et al.* The impact of preexisting mental health disorders  
652 on the diagnosis, treatment, and survival among lung cancer patients in the US  
653 military health system. *Cancer Epidemiol Prev Biomarkers* 2016; **25**: 1564–71.
- 654 4 Pitman A, Suleman S, Hyde N, Hodgkiss A. Depression and anxiety in patients with  
655 cancer. *BMJ* 2018; **361**: 1–6.
- 656 5 Shi W, Shen Z, Wang S, Hall BJ. Barriers to professional mental health help-seeking  
657 among Chinese adults: a systematic review. *Front psychiatry* 2020; **11**: 442.
- 658 6 Phillips MR, Zhang J, Shi Q, *et al.* Prevalence, treatment, and associated disability of  
659 mental disorders in four provinces in China during 2001--05: an epidemiological  
660 survey. *Lancet* 2009; **373**: 2041–53.
- 661 7 Nohr L, Lorenzo Ruiz A, Sandoval Ferrer JE, Buhlmann U. Mental health stigma and  
662 professional help-seeking attitudes a comparison between Cuba and Germany. *PLoS*  
663 *One* 2021; **16**: e0246501.
- 664 8 Henson KE, Brock R, Charnock J, Wickramasinghe B, Will O, Pitman A. Risk of  
665 suicide after cancer diagnosis in England. *Jama Psychiatry* 2019; **76**: 51–60.
- 666 9 Herrett E, Gallagher AM, Bhaskaran K, *et al.* Data resource profile: clinical practice  
667 research datalink (CPRD). *Int J Epidemiol* 2015; **44**: 827–36.
- 668 10 Dong H, Robison LL, Leisenring WM, Martin LJ, Armstrong GT, Yasui Y. Estimating  
669 the burden of recurrent events in the presence of competing risks: The method of  
670 mean cumulative count. *Am J Epidemiol* 2015; **181**: 532–40.
- 671 11 Lai AG, Pasea L, Banerjee A, *et al.* Estimated impact of the COVID-19 pandemic on  
672 cancer services and excess 1-year mortality in people with cancer and multimorbidity:  
673 near real-time data on cancer care, cancer deaths and a population-based cohort  
674 study. *BMJ Open* 2020; **10**. DOI:10.1136/bmjopen-2020-043828.
- 675 12 Denaxas S, Gonzalez-Izquierdo A, Direk K, *et al.* UK phenomics platform for  
676 developing and validating electronic health record phenotypes: CALIBER. *J Am Med*  
677 *Informatics Assoc* 2019.
- 678 13 Kuan V, Denaxas S, Gonzalez-Izquierdo A, *et al.* A chronological map of 308 physical  
679 and mental health conditions from 4 million individuals in the English National Health  
680 Service. *Lancet Digit Heal* 2019; **1**: e63–77.
- 681 14 Morgan C, Webb RT, Carr MJ, *et al.* Self-harm in a primary care cohort of older  
682 people: incidence, clinical management, and risk of suicide and other causes of  
683 death. *The Lancet Psychiatry* 2018; **5**: 905–12.
- 684 15 Bhakta N, Liu Q, Ness KK, *et al.* The cumulative burden of surviving childhood  
685 cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE). *Lancet*  
686 2017; **390**: 2569–82.
- 687 16 Plana-Ripoll O, Canudas-Romo V, Weye N, Laursen TM, McGrath JJ, Andersen PK.  
688 lillies: An R package for the estimation of excess Life Years Lost among patients with  
689 a given disease or condition. *PLoS One* 2020; **15**: e0228073.
- 690 17 Erlangsen A, Andersen PK, Toender A, Laursen TM, Nordentoft M, Canudas-Romo  
691 V. Cause-specific life-years lost in people with mental disorders: a nationwide,  
692 register-based cohort study. *The Lancet Psychiatry* 2017; **4**: 937–45.
- 693 18 Plana-Ripoll O, Pedersen CB, Agerbo E, *et al.* A comprehensive analysis of mortality-  
694 related health metrics associated with mental disorders: a nationwide, register-based  
695 cohort study. *Lancet* 2019; **394**: 1827–35.
- 696 19 Laursen TM, Plana-Ripoll O, Andersen PK, *et al.* Cause-specific life years lost among  
697 persons diagnosed with schizophrenia: is it getting better or worse? *Schizophr Res*  
698 2019; **206**: 284–90.

- 699 20 Chai Y, Luo H, Wong GHY, *et al.* Risk of self-harm after the diagnosis of psychiatric  
700 disorders in Hong Kong, 2000–10: a nested case-control study. *The Lancet*  
701 *Psychiatry* 2020; **7**: 135–47.
- 702 21 Choi EK, Kim I-R, Chang O, *et al.* Impact of chemotherapy-induced alopecia distress  
703 on body image, psychosocial well-being, and depression in breast cancer patients.  
704 *Psychooncology* 2014; **23**: 1103–10.
- 705 22 Maheu C, Singh M, Tock WL, *et al.* Fear of Cancer Recurrence, Health Anxiety,  
706 Worry, and Uncertainty: A Scoping Review About Their Conceptualization and  
707 Measurement Within Breast Cancer Survivorship Research. *Front Psychol* 2021; **12**:  
708 1129.
- 709 23 McFarland DC, Morita J, Alici Y. Personality Disorders in Patients with Cancer. *Oncol*  
710 2019; **33**.
- 711 24 Krebber AMH, Buffart LM, Kleijn G, *et al.* Prevalence of depression in cancer patients:  
712 a meta-analysis of diagnostic interviews and self-report instruments. *Psychooncology*  
713 2014; **23**: 121–30.
- 714 25 Naser AY, Hameed AN, Mustafa N, *et al.* Depression and Anxiety in Patients With  
715 Cancer: A Cross-Sectional Study. *Front Psychol* 2021; **12**.
- 716 26 Breitbart W, Rosenfeld B, Tobias K, *et al.* Depression, cytokines, and pancreatic  
717 cancer. *Psychooncology* 2014; **23**: 339–45.
- 718 27 Kayser MS, Kohler CG, Dalmau J. Psychiatric manifestations of paraneoplastic  
719 disorders. *Am J Psychiatry* 2010; **167**: 1039–50.
- 720 28 Rees JH. Paraneoplastic syndromes: when to suspect, how to confirm, and how to  
721 manage. *J Neurol Neurosurg & Psychiatry* 2004; **75**: ii43--ii50.
- 722 29 Depp CA, Jeste D V. Bipolar disorder in older adults: a critical review. *Bipolar Disord*  
723 2004; **6**: 343–67.
- 724 30 Warren KN, Katakam J, Espiridion ED. Acute-onset mania in a patient with non-small  
725 cell lung cancer. *Cureus* 2019; **11**.
- 726 31 Kenna HA, Poon AW, de los Angeles CP, Koran LM. Psychiatric complications of  
727 treatment with corticosteroids: review with case report. *Psychiatry Clin Neurosci* 2011;  
728 **65**: 549–60.
- 729 32 Ha JH, Hwang D-Y, Yu J, Park D-H, Ryu S-H. Onset of manic episode during  
730 chemotherapy with 5-fluorouracil. *Psychiatry Investig* 2011; **8**: 71.
- 731 33 Choi SM, Lee SH, Yang YS, Kim BC, Kim MK, Cho KH. 5-fluorouracil-induced  
732 leukoencephalopathy in patients with breast cancer. *J Korean Med Sci* 2001; **16**: 328–  
733 34.
- 734 34 Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. *Lancet Neurol*  
735 2008; **7**: 327–40.
- 736 35 Collins C, Oakley-Browne M. Mania associated with small cell carcinoma of the lung.  
737 *Aust N Z J Psychiatry* 1988; **22**: 207–9.
- 738 36 El Hayek S, El-Khoury J. Late-onset mania associated with corticosteroids and small  
739 cell lung carcinoma. *BMJ Case Reports CP* 2020; **13**: e233403.
- 740 37 Fond G, Salas S, Pauly V, *et al.* End-of-life care among patients with schizophrenia  
741 and cancer: a population-based cohort study from the French national hospital  
742 database. *Lancet Public Heal* 2019; **4**: e583--e591.
- 743 38 Irwin KE, Henderson DC, Knight HP, Pirl WF. Cancer care for individuals with  
744 schizophrenia. *Cancer* 2014; **120**: 323–34.
- 745 39 Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a  
746 reexamination. *Arch Gen Psychiatry* 2005; **62**: 247–53.
- 747 40 Härtl K, Engel J, Herschbach P, Reinecker H, Sommer H, Friese K. Personality traits  
748 and psychosocial stress: quality of life over 2 years following breast cancer diagnosis  
749 and psychological impact factors. *Psycho-Oncology J Psychol Soc Behav Dimens*  
750 *Cancer* 2010; **19**: 160–9.
- 751 41 Grov EK, Fosså SD, Bremnes RM, *et al.* The personality trait of neuroticism is  
752 strongly associated with long-term morbidity in testicular cancer survivors. *Acta Oncol*  
753 (*Madr*) 2009; **48**: 842–9.

754 42 Linsley KR, Schapira K, Kelly TP. Open verdict v. suicide--importance to research. *Br*  
755 *J Psychiatry* 2001; **178**: 465–8.

756 43 Benros ME, Laursen TM, Dalton SO, Mortensen PB. Psychiatric disorder as a first  
757 manifestation of cancer: A 10-year population-based study. *Int J cancer* 2009; **124**:  
758 2917–22.

759 44 Galasko D, Kwo-On-Yuen PF, Thal L. Intracranial mass lesions associated with late-  
760 onset psychosis and depression. *Psychiatr Clin North Am* 1988; **11**: 151–66.

761 45 Li M, Kennedy EB, Byrne N, *et al.* Management of depression in patients with cancer:  
762 a clinical practice guideline. *J Oncol Pract* 2016; **12**: 747–56.

763 46 Stonier T, Harrison M. Preventing the co-prescription of tamoxifen and fluoxetine in  
764 General Practice. *BMJ Open Qual* 2013; **2**: u201015--w675.

765 47 Sharpe M, Walker J, Hansen CH, *et al.* Integrated collaborative care for comorbid  
766 major depression in patients with cancer (SMaRT Oncology-2): a multicentre  
767 randomised controlled effectiveness trial. *Lancet* 2014; **384**: 1099–108.

768 48 Peteet JR, Meyer FL, Miovic MK. Possibly impossible patients: management of  
769 difficult behavior in oncology outpatients. *J Oncol Pract* 2011; **7**: 242–6.  
770  
771

772 **Main figure legends**

773

774 Figure 1. Cumulative burden of psychiatric disorders in patients with cancer. Distribution of  
775 cumulative burden by (A) 26 cancer diagnostic groups, (B) 10 cancer treatment modalities and  
776 (C) 11 chemotherapy drug class. All data and 95% confidence intervals are provided in the  
777 supplementary tables.

778

779 Figure 2. Temporal variation in the first diagnosis of psychiatric disorder in relation to the time  
780 of the first occurrence of self-harm. (A) By cancer type. (B) By age group. (C) By Index of  
781 Multiple Deprivation (IMD) status. (D) By the number of prevalent non-cancer comorbidities.  
782 Bars on the left side of the graphs indicate the proportion of individuals being diagnosed with  
783 a psychiatric disorder before the first self-harm event. Bars on the right side of the graphs  
784 indicate the proportion of individuals being diagnosed with a psychiatric disorder after the first  
785 self-harm event. Prevalence ratios (prevalence of psychiatric disorder diagnosis before self-  
786 harm divided by prevalence of psychiatric disorder after self-harm) were shown, alongside  
787 95% confidence intervals.

788

789 Figure 3. Total burden and risk of self-harm after diagnosis of psychiatric disorders in patients  
790 with cancer. Case (with psychiatric disorder) and control (no psychiatric disorder) groups were  
791 obtained via propensity score matching (see Figure S1). Controls were matched by age at  
792 cancer diagnosis, cancer type, sex, Index of Multiple Deprivation and primary care practice  
793 ID. (A) Cumulative burden of self-harm events in cases and controls. (B) Hazard ratios for risk  
794 of self-harm for each psychiatric disorder were further adjusted for non-cancer comorbidities,  
795 cancer treatment and presence of other psychiatric disorders. Self-harm risks during the first  
796 12 months and subsequent years of follow-up were shown. Strata with low event numbers ( $n$   
797  $< 10$ ) were not analysed. All data and 95% confidence intervals are provided in the  
798 supplementary tables.

799

800 Figure 4. Cumulative incidence of all-cause mortality and years of life lost after diagnosis of  
801 psychiatric disorders in patients with cancer. Case (with psychiatric disorder) and control (no  
802 psychiatric disorder) groups were obtained via propensity score matching (see Figure S1).  
803 Controls were matched by age at cancer diagnosis, cancer type, sex, Index of Multiple  
804 Deprivation and primary care practice ID. (A) Cumulative incidence curves for all-cause  
805 mortality after psychiatric disorder diagnosis in matched case and control groups. (B) Excess  
806 years of life lost (YLL) attributable to psychiatric disorders in patients with cancer. Radar plots  
807 depict the difference in YLL between matched cases and controls. Excess YLL was estimated  
808 based on the age of onset of a psychiatric disorder. All data and 95% confidence intervals are  
809 provided in the supplementary tables.


810

811 Figure 5. Risk of suicide and other causes of death following self-harm in patients with cancer.  
812 Case (self-harm) and control (no self-harm) groups were obtained via propensity score  
813 matching (see Figure S2). Controls were matched by age at cancer diagnosis, cancer type,  
814 sex, Index of Multiple Deprivation and primary care practice ID. (A) Hazard ratios for risk of  
815 suicide and other causes of death were further adjusted for non-cancer comorbidities, cancer  
816 treatment and presence of psychiatric disorders. Mortality risks during the first 12 months and  
817 subsequent years of follow-up were shown. (B) Cumulative incidence curves of death due to  
818 all causes, natural causes and unnatural causes after self-harm in matched case and control  
819 groups.


820

Figure 1. Cumulative burden of psychiatric disorders in patients with cancer. Distribution of cumulative burden by (A) 26 cancer diagnostic groups, (B) 10 cancer treatment modalities and (C) 11 chemotherapy drug class. All data and 95% confidence intervals are provided in the supplementary tables.

A



B



C






Figure 2. Temporal variation in the first diagnosis of psychiatric disorder in relation to the time of the first occurrence of self-harm. (A) By cancer type. (B) By age group. (C) By Index of Multiple Deprivation (IMD) status. (D) By number of prevalent non-cancer comorbidities. Bars on the left side of the graphs indicate the proportion of individuals being diagnosed with a psychiatric disorder before the first self-harm event. Bars on the right side of the graphs indicate the proportion of individuals being diagnosed with a psychiatric disorder after the first self-harm event. Prevalence ratios (prevalence of psychiatric disorder diagnosis before self-harm divided by prevalence of psychiatric disorder after self-harm) were shown, alongside 95% confidence intervals.


A



B



C



D




Figure 3. Total burden and risk of self-harm after diagnosis of psychiatric disorders in patients with cancer. Case (with psychiatric disorder) and control (no psychiatric disorder) groups were obtained via propensity score matching (see Figure S1). Controls were matched by age at cancer diagnosis, cancer type, sex, Index of Multiple Deprivation and primary care practice ID. (A) Cumulative burden of self-harm events in cases and controls. (B) Hazard ratios for risk of self-harm for each psychiatric disorder were further adjusted for non-cancer comorbidities, cancer treatment and presence of other psychiatric disorders. Self-harm risks during the first 12 months and subsequent years of follow-up were shown. Strata with low event numbers ( $n < 10$ ) were not analysed. All data and 95% confidence intervals are provided in the supplementary tables.





Figure 4. Cumulative incidence of all-cause mortality and years of life lost after diagnosis of psychiatric disorders in patients with cancer. Case (with psychiatric disorder) and control (no psychiatric disorder) groups were obtained via propensity score matching (see Figure S1). Controls were matched by age at cancer diagnosis, cancer type, sex, Index of Multiple Deprivation and primary care practice ID. (A) Cumulative incidence curves for all-cause mortality after psychiatric disorder diagnosis in matched case and control groups. (B) Excess years of life lost (YLL) attributable to psychiatric disorders in patients with cancer. Radar plots depict the difference in YLL between matched cases and controls. Excess YLL was estimated based on the age of onset of a psychiatric disorder. All data and 95% confidence intervals are provided in the supplementary tables.





Figure 5. Risk of suicide and other causes of death following self-harm in patients with cancer. Case (self-harm) and control (no self-harm) groups were obtained via propensity score matching (see Figure S2). Controls were matched by age at cancer diagnosis, cancer type, sex, Index of Multiple Deprivation and primary care practice ID. (A) Hazard ratios for risk of suicide and other causes of death were further adjusted for non-cancer comorbidities, cancer treatment and presence of psychiatric disorders. Mortality risks during the first 12 months and subsequent years of follow-up were shown. (B) Cumulative incidence curves of death due to all causes, natural causes and unnatural causes after self-harm in matched case and control groups.

